Mano T, Kawamoto K, Miyake T, Torigoe T
Department of Obstetrics and Gynecology, Shuto Hospital, Yamaguchi.
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Sep;41(9):1439-45.
The clinical value of OK-432 treatments, was evaluated in 215 patients with various types of gynecologic cancer. Five KE OK-432 was administrated by intramuscular injection every other day for up to 5 years, unless severe side-effects were observed. The 5-year survival rate was determined in 51 patients in the OK-432 group and 93 patients in the control group. The survival rate in the OK-432 group was significantly higher in the cervical cancer patients in stages III and IV than in the control group, at from 20 to 29 months and from 37 to 42 months. These results indicated that long period administration of OK-432 might improve the survival rate in patients with gynecologic cancer, especially in those with advanced cervical cancer.
对215例不同类型妇科癌症患者评估了OK-432治疗的临床价值。除非观察到严重副作用，每间隔一天通过肌肉注射给予5KE OK-432，持续长达5年。在OK-432组的51例患者和对照组的93例患者中测定了5年生存率。OK-432组中III期和IV期宫颈癌患者的生存率在20至29个月以及37至42个月时显著高于对照组。这些结果表明，长期给予OK-432可能提高妇科癌症患者的生存率，尤其是晚期宫颈癌患者。
